A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination with Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients with Pancreatic Cancer

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Pancreatic Cancer
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Presence of pancreatic ductal adenocarcinoma (PDAC) based on the examination of tissue or cells
    2. Tumor is located only in the pancreas and has been determined to be either resectable or borderline resectable (can be potentially surgica

You may not be eligible for this study if the following are true:

    1. Diagnosis of pancreatic neuroendocrine carcinoma or pancreatic acinar cell carcinoma
    2. Been determined by the medical or surgical team to be a poor candidate for future surgical resection
    3. Previous immunotherapy for pancreatic

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.